These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19236265)

  • 1. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combretastatin A4 phosphate: a novel vascular disrupting agent.
    Nagaiah G; Remick SC
    Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combretastatin A4 phosphate: background and current clinical status.
    Young SL; Chaplin DJ
    Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
    Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
    Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combretastatin A4 phosphate.
    West CM; Price P
    Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
    Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
    World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour vascular disrupting agents: combating treatment resistance.
    Tozer GM; Kanthou C; Lewis G; Prise VE; Vojnovic B; Hill SA
    Br J Radiol; 2008 Oct; 81 Spec No 1():S12-20. PubMed ID: 18819993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development and use of vascular targeted therapy in ovarian cancer.
    Chase DM; Chaplin DJ; Monk BJ
    Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of combretastatin A4 phosphate as a vascular targeting agent.
    Chaplin DJ; Hill SA
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
    Cooney MM; Ortiz J; Bukowski RM; Remick SC
    Curr Oncol Rep; 2005 Mar; 7(2):90-5. PubMed ID: 15717941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
    Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells.
    Ding X; Zhang Z; Li S; Wang A
    Oncol Res; 2011; 19(7):303-9. PubMed ID: 21936400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
    Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.
    Williams LJ; Mukherjee D; Fisher M; Reyes-Aldasoro CC; Akerman S; Kanthou C; Tozer GM
    Br J Pharmacol; 2014 Nov; 171(21):4902-13. PubMed ID: 24930520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
    Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
    Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
    Dalal S; Burchill SA
    Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
    Liu L; Mason RP; Gimi B
    Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
    Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
    Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.